TABLE 1

Patient and clinical characteristics of patients hospitalised for COVID-19

n#All (n=492)
Patient characteristic
Age years60.2±10.7
Sex, male335 (68.1)
BMI kg·m−243729.3±5.5
Migration background491
  European373 (76.0)
  Dutch Caribbean61 (12.4)
  Asian25 (5.1)
  Turkish18 (3.7)
  (North) African14 (2.9)
Pre-COVID education489
  Low166 (33.9)
  Middle172 (35.2)
  High151 (30.9)
Pre-COVID employment490
  Unemployed77 (15.7)
  Employed297 (60.6)
  Retired116 (23.7)
Smoking status491
  Never211 (43.0)
  Former270 (55.0)
  Current10 (2.0)
Comorbidities
  ≥1403 (81.9)
  Obesity (BMI ≥30)190 (38.6)
  Diabetes95 (19.3)
  Cardiovascular disease/hypertension192 (39.0)
  Pulmonary disease119 (24.2)
  Renal disease46 (9.3)
  Gastrointestinal disease22 (4.5)
  Neuromuscular disease49 (10.0)
  Malignancy56 (11.4)
  Autoimmune/inflammatory disease54 (11.0)
  Mental disorder25 (5.1)
In-hospital characteristics
PCR confirmed SARS-CoV-2485 (98.6)
Serology confirmed SARS-CoV-27 (1.4)
Laboratory values
  Creatinine µmol·L−147182.0 (69.0–100.0)
  (CKD-EPI) eGFR mL·min−145682.0 (66.0–90.0)
  CRP mg·L−146785.0 (47.0–154.0)
  Ferritin µg·L−1284832.5 (443.5–1613.3)
  ALAT U·L−145737.0 (26.0–56.0)
  Haemoglobin mmol·L−14688.6 (7.9–9.2)
  MCV fL46189.0 (85.0–91.0)
  Thrombocytes, 10⁹/L463211.0 (159.0–276.0)
  Lymphocytes absolute count, 10⁹/L3250.9 (0.6–1.1)
  D-dimer mg·L−12371.1 (0.6–380.0)
  NT-proBNP pmol·mL−19018.5 (8.8–48.0)
  IL-6 pmol·mL−13655.5 (28.0–179.0)
Chest radiograph abnormalities468
  Normal59 (12.6)
  Moderate99 (21.2)
  Severe310 (66.2)
Thrombosis48479 (16.3)
Delirium477121 (25.4)
Requiring oxygen supplementation492474 (96.3)
Requiring high-flow nasal cannula462150 (32.5)
ICU admission199 (40.4)
  Invasive mechanical ventilation175 (35.6)
  Length of intubation days16714.0 (8.0–27.0)
  Tracheostomy48264 (13.3)
  Length of ICU stay days19717.0 (9.0–30.5)
Length of hospital stay days11.0 (6.0–27.0)
COVID-19 directed treatment466
  None109 (23.4)
  (Hydroxy)chloroquine14 (3.0)
  Steroids330 (70.8)
  Antivirals69 (14.8)
  Anti-inflammatory (IL-6) treatment54 (11.6)
  Convalescent plasma8 (1.7)
  Monoclonal antibodies0 (0.0)
Time interval between discharge and follow-up visit
3-month visit, days38594.7±22.8
6-month visit, days483184.8±27.9
12-month visit, days271368.3±17.3

Data are presented as n (%), mean±sd or, for non-normally distributed variables, median (interquartile range). BMI: body mass index; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; NT-proBNP: N-terminal pro-brain natriuretic peptide; IL-6: interleukin-6; ICU: intensive care unit. #: adjusted n is presented for variables with a total number of patients <492.